Lindner Center of HOPE, Mason, OH 45040, USA.
Eat Behav. 2013 Jan;14(1):87-9. doi: 10.1016/j.eatbeh.2012.11.001. Epub 2012 Nov 19.
The objective of this 12-week open-label flexible-dose study was to preliminarily assess the effectiveness of N-acetylcysteine (NAC) in bulimia nervosa (BN). The primary outcome was binge-purge episode frequency. Eight individuals with BN by DSM-IV criteria received NAC, but only two completed the study. NAC was not associated with significant reductions in frequency of binge-purge episodes or measures of clinical severity, eating, or mood pathology. In this trial, NAC was ineffective in BN and was associated with a high discontinuation rate.
本为期 12 周的开放性标签灵活剂量研究旨在初步评估 N-乙酰半胱氨酸 (NAC) 在神经性贪食症 (BN) 中的疗效。主要结局是暴食-催吐发作频率。8 名符合 DSM-IV 标准的 BN 患者接受了 NAC，但只有 2 人完成了研究。NAC 与暴食-催吐发作频率或临床严重程度、饮食或情绪病理的衡量标准的显著减少无关。在这项试验中，NAC 在 BN 中无效，并与高停药率相关。
